ADHD in children and youth: Part 3-Assessment and treatment with comorbid ASD, ID, or prematurity

Brenda Clark1, Stacey A Bélanger1

  • 1Canadian Paediatric Society, Mental Health and Developmental Disabilities Committee, Ottawa, Ontario.

Insights

Canadian guidelines offer evidence-based ADHD care standards for children and youth. This review covers diagnosis, common presentations, genetics, and treatment for attention-deficit hyperactivity disorder (ADHD), including associated conditions.

Area of Science:

  • Neurodevelopmental disorders
  • Pediatric medicine
  • Clinical evidence synthesis

Background:

  • Attention-deficit hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder impacting children and youth.
  • Existing clinical evidence requires systematic review to establish standardized care protocols.
  • Canadian Paediatric Society developed three position statements based on literature reviews.

Purpose of the Study:

  • To summarize current clinical evidence for ADHD.
  • To establish a standard of care for ADHD in Canada.
  • To aid clinicians in evidence-based decision-making for pediatric ADHD management.

Main Methods:

  • Systematic literature reviews were conducted.
  • Focus on Part 3: associated autism spectrum disorder, intellectual disability, and prematurity.
  • Recommendations based on guidelines, literature, and expert consensus.

Main Results:

  • Comprehensive review of ADHD diagnostic challenges and presentations.
  • Exploration of genetic factors in ADHD.
  • Evaluation of treatment options, including physical activity benefits.

Conclusions:

  • Evidence-based recommendations for ADHD care are provided.
  • Standardized care aims to enhance outcomes for children and youth with ADHD.
  • Part 3 addresses complex cases involving co-occurring conditions.

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
292
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH301:11

orthopara-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3

All ortho–para directors, excluding halogens, are activating groups. These groups donate electrons to the ring, making the ring carbons electron-rich. Consequently, the reactivity of the aromatic ring towards electrophilic substitution increases. For instance, the nitration of anisole is about 10,000 times faster than the nitration of benzene. The electron-donating effect of the methoxy group in anisole activates the ortho and para positions on the ring and stabilizes the corresponding...
7.5K
Piaget's Stage 3 of Cognitive Development01:17

Piaget's Stage 3 of Cognitive Development

During Piaget's concrete operational stage, from ages 7 to 11, children exhibit a marked increase in logical thinking skills, specifically in relation to tangible, real-world events. This stage is characterized by the development of several essential cognitive concepts, including conservation, reversibility, and classification, all of which support the child's evolving capacity for structured thought.
Conservation and Constancy of Quantity
A significant cognitive milestone in the...
1.1K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
993
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K